Notably, altering IKBKE expression did not further influence cell growth or sunitinib sensitivity when RRM2 was knocked down in renal cancer cells, demonstrating that IKBKE primarily modulates cell growth and sunitinib sensitivity through the RRM2-mediated AKT pathway. The gene discussed is RRM2; the disease is renal carcinoma.